JOHN MILNER: Open Payments
NPI 1558026021 · SACRAMENTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,181 in 53 payments from 14 companies in 2025. Trend: 2023 $71 · 2024 $877 · 2025 $1,181
Food & beverage: $1,097Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $231 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $154 |
| Novo Nordisk Inc | 1 | $125 |
| GENZYME CORPORATION | 1 | $122 |
| Janssen Biotech, Inc. | 2 | $106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $93 |
| Aimmune Therapeutics, Inc. | 3 | $91 |
| Gilead Sciences, Inc. | 2 | $59 |
| Regeneron Healthcare Solutions, Inc. | 2 | $57 |
| Ardelyx, Inc. | 2 | $49 |
Products named: DUPIXENT, Wegovy, XIFAXAN, TREMFYA, ENTYVIO, ZENPEP, LINZESS, SKYRIZI.
Industry payments across CA — which companies pay providers there.
